These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 31633473)

  • 1. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
    Ohmoto A; Morizane C
    Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
    Abdel-Rahman O; Fouad M
    Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of advanced high grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature.
    Mohamed A; Trybula M; Asa SL; Halfdanarson TR; Sonbol MB
    Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39133180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
    Weber MM; Fottner C
    Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
    Kawasaki K; Fujii M; Sato T
    Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
    Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
    Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) - Current literature review of diagnostics and therapy. What has changed in the management?
    Jurkiewicz K; Miciak M; Kaliszewski K
    Pol Przegl Chir; 2024 Mar; 96(4):58-66. PubMed ID: 39138986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
    Xu JX; Wu DH; Ying LW; Hu HG
    World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
    Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
    Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
    Ooki A; Osumi H; Fukuda K; Yamaguchi K
    Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.
    Stefàno E; De Castro F; Ciccarese A; Muscella A; Marsigliante S; Benedetti M; Fanizzi FP
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Alexandraki KI; Daskalakis K; Tsoli M; Grossman AB; Kaltsas GA
    Trends Endocrinol Metab; 2020 Mar; 31(3):239-255. PubMed ID: 31839442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
    Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
    Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.